迪哲醫藥(688192.SH)：舒沃替尼(DZD9008)研究成果在 《Cancer Discovery》發表
格隆匯5月4日丨迪哲醫藥(688192.SH)公佈，近日，公司自主研發的全球首創小分子化合物舒沃替尼(DZD9008)的藥物研發、轉化科學和臨牀研究成果發表在國際頂級期刊《Cancer Discovery》(《癌症發現》，影響因子：39.397)網站。舒沃替尼是迪哲針對EGFR突變導致的非小細胞肺癌而設計的新一代靶向藥物。美國哈佛大學醫學院附屬丹娜法伯癌症研究院(Dana-Farber Cancer Institute) Pasi A. Jänne 教授為本文的通訊作者，北京協和醫院呼吸與危重症醫學科王孟昭教授和台灣大學醫學院附設醫院癌醫中心分院楊志新(James Chih-Hsin Yang)教授為文章的共同第一作者。
《Cancer Discovery》是美國癌症研究協會(AACR)出版集團的核心刊物，發表具有高影響力、經同行評審、支持臨牀試驗的基礎研究和轉化科學領域的全球重大成果進展，主要發文機構為全球著名高校和尖端腫瘤研究機構。
公司在研產品舒沃替尼研究成果被腫瘤領域SCI影響因子全球前十大國際頂尖期刊收錄，彰顯了迪哲醫藥在分子發現、轉化科學領域的全球競爭力。立足於對 EGFR 領域的深刻理解，公司從EGFR 20號外顯子插入突變非小細胞肺癌(EGFR Exon20ins NSCLC)這一未被滿足的臨牀需求出發，通過對EGFR 20號外顯子插入突變的蛋白結構以及已有EGFR-TKI化學結構的分析，經過多輪設計、合成、測試，研發出舒沃替尼這一高效、高選擇性及具有良好藥代動力學特徵的全新一代EGFR-TKI，能夠有效抑制EGFR 20號外顯子插入突變，並對EGFR敏感突變、T790M雙突變和罕見突變均有效，同時保持對野生型EGFR的高選擇性。舒沃替尼於2019年7月完成首例受試者給藥，現處於全球關鍵性註冊臨牀試驗階段，公司轉化科學的差異化競爭優勢有效提升了新藥研發的進度和成功率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
